Company History
February 2019
Acquired RNA-loaded dendritic cell platform technology and assets of Argos Therapeutics
February 2019
February 2019
coIMMUNE incorporated in Delaware
February 2019
April 2020
Acquired CAR-CIK platform technology through acquisition of Formula Pharmaceuticals
April 2020
July 2020
Initiated Phase 2b coIMMUNE-sponsored RNA-loaded DC trial for RCC (CMN-001)
July 2020
October 2020
Completed $45M Series A financing
October 2020
December 2020
Completed investigator-initiated Phase 1/2a CAR-CIK trial for ALL (CMN-005)
December 2020
October 2021
Partnership with cancer center for CAR-CIK in solid tumors
October 2021
2H 2021
Started investigator-initiated repeat dosing trial with CMN-005 in ALL
2H 2021
2H 2021
Start investigator-initiated CMN-005 NHL trial
2H 2021
1Q 2022
Start investigator initiated CMN-005 NHL/CLL trial
1Q 2022